<SEC-DOCUMENT>0001104659-20-004310.txt : 20200115
<SEC-HEADER>0001104659-20-004310.hdr.sgml : 20200115
<ACCEPTANCE-DATETIME>20200115160133
ACCESSION NUMBER:		0001104659-20-004310
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200115
DATE AS OF CHANGE:		20200115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Replimune Group, Inc.
		CENTRAL INDEX KEY:			0001737953
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				822082553
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38596
		FILM NUMBER:		20528309

	BUSINESS ADDRESS:	
		STREET 1:		500 UNICORN PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		(781) 222-9600

	MAIL ADDRESS:	
		STREET 1:		500 UNICORN PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm203473d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or
15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>January 13, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPLIMUNE GROUP, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-38596</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>82-2082553</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission<BR>
File Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer<BR>
Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>500 Unicorn Park</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Woburn, MA 01801 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(781) 222-9600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))<BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 52%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt">REPL</FONT></TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-top: 6pt; padding-bottom: 6pt; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC (Nasdaq Global Select Market)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).&nbsp;&nbsp;Emerging growth company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Wingdings; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Wingdings; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Wingdings; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Wingdings; margin: 0pt 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 10%"><FONT STYLE="font-size: 10pt"><B>Item 2.02</B></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt"><B>Results of Operations and Financial Condition. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discusses below,
on January 13, 2020, Replimune Group, Inc. (the &ldquo;Company&rdquo;) issued a press release which contained information regarding
the Company&rsquo;s preliminary, unaudited estimate of cash, cash equivalents and short-term investments as of December 31, 2019
of approximately $183 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial results
included in the press release are unaudited and preliminary estimates that (i) represent the most current information available
to management as of the date of this Current Report on Form 8-K, (ii) are subject to completion of financial closing and procedures
that could result in significant changes to the estimated amounts, and (iii) do not present all information necessary for an understanding
of the Company&rsquo;s financial condition as of, and its results of operations for the year ended, December 31, 2019. Accordingly,
undue reliance should not be placed on such preliminary estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
General Instruction B.2. of Form 8-K, the information in this Item 2.02 shall not be deemed &ldquo;filed&rdquo; for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall
it be deemed incorporated by reference in any of the Company&rsquo;s filings under the Securities Act of 1933, as amended, whether
made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 10%"><FONT STYLE="font-size: 10pt"><B>Item 7.01</B></FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 13, 2020,
the Company issued a press release providing a 2019 year end corporate update and reviewing expected 2020 milestones. A copy of
the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update,
supplement or amend the materials attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information contained
in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing of the Company, whether
made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated
by specific reference to such filing. The information in this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to
be &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibit No. </FONT></TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibit Name</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="tm203473d1_ex99-1.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="tm203473d1_ex99-1.htm"><FONT STYLE="font-size: 10pt">Replimune Group, Inc. Press Release, dated January 13, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>REPLIMUNE GROUP, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: January 15, 2020</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Philip Astley-Sparke</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Philip Astley-Sparke</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm203473d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm203473d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>Replimune Provides 2019 Year End Corporate Update
and Reviews Expected 2020 Milestones</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">January 13, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>RP1:
Registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (Libtayo<SUP>&reg;</SUP>)
in cutaneous squamous cell carcinoma (CSCC) underway</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>RP1: Study of RP1 as
a monotherapy in solid organ transplant recipients with CSCC on track to initiate in H1 2020 with initial data expected by year-end</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>RP1: Additional Phase
2 readouts expected during 2020 in melanoma, non-melanoma skin cancers, bladder cancer and microsatellite instability-high (MSI-H)
tumors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>RP1:
125 patient Phase 2 cohort of RP1 combined with Opdivo<SUP>&reg;</SUP> (nivolumab) in anti-PD-1 refractory melanoma on track
to initiate in H1 2020</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17pt 0pt 44pt; text-indent: -25.55pt"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><I>RP2: Phase 1 clinical trial of RP2 as monotherapy and in combination with Opdivo underway, with
initial data expected in 2020</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>RP3: Phase 1 clinical trial of RP3 as monotherapy
and in combination with an anti-PD-1 remains on track to initiate in 2020</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17pt 0pt 1pt">WOBURN, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) --
Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic&trade;
platform, today provided a corporate update, highlighting the progress of its key programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Replimune had a very productive 2019 where a key
highlight included the presentation of initial clinical data with RP1 as monotherapy and combined with Opdivo at the 34th
Annual Meeting of the Society for Immunotherapy of Cancer,&rdquo; said Philip Astley-Sparke, Chief Executive Officer of
Replimune. &ldquo;We believe the data provides strong support for our ongoing registration-directed trial in our lead
indication of CSCC as well as the decision to initiate a new clinical trial in organ transplant recipients who have developed
the disease. Similarly, the data in melanoma led to the decision to expand the clinical trial to include a
registration-directed cohort of melanoma patients who are refractory to prior treatment with anti-PD1 therapy. We also
initiated our first clinical trial of RP2, the next therapy in our pipeline. Overall we are thrilled with our progress and
are excited for the year ahead as we release further data sets, bring our third product into the clinic to address less
immune-responsive tumors and as we continue to execute upon our mission to make our oncolytic immuno-gene therapies a
cornerstone of cancer treatment.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>Program Updates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 1pt"><B>RP1: </B>RP1 is Replimune&rsquo;s first clinical
product candidate and is based on a proprietary new strain of herpes simplex virus armed with a gene encoding a potent fusogenic
protein (GALV-GP-R-), intended to enhance tumor killing potency, immunogenic cell death and the activation of systemic anti-tumor
immune responses, and with a gene encoding the cytokine GM-CSF. The Company presented initial data from the Phase 1/2 clinical
trial of RP1 alone and in combination with Opdivo in November 2019 at SITC 2019. The Company believes the data demonstrates that
RP1 used alone and in combination with Opdivo is well tolerated and showed preliminary anti-tumor efficacy in target tumor types
providing strong support for its ongoing and planned development programs in melanoma and CSCC. This clinical trial is being conducted
under a clinical trial collaboration and agreement with Bristol-Myers Squibb (BMS) for the supply of Opdivo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Recent RP1-specific program progress is summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 31pt; text-indent: -9.1pt">&bull;&nbsp;&nbsp;The registration-directed Phase 2 clinical trial of RP1 in combination with Libtayo in CSCC is underway. This multi-center, randomized,
controlled clinical trial is intended to enroll approximately 240 patients with CSCC. The clinical trial&rsquo;s primary objective
is to compare the response rate following treatment with RP1 in combination with Libtayo to the response rate achieved with Libtayo
alone. Libtayo is an FDA-approved anti-PD-1 therapy developed by Regeneron and Sanofi for the treatment of patients with metastatic
or locally-advanced CSCC who are not candidates for curative surgery or radiation. This clinical trial is being conducted under
the Company&rsquo;s collaboration agreement with Regeneron, whereby the Company and Regeneron split development and supply costs
equally. Recruitment for this clinical trial is expected to take approximately 18 to 24 months and enroll patients in the United
States, Australia, Canada, United Kingdom and European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 31pt; text-indent: -9.1pt">&bull;&nbsp;&nbsp;Recruitment is currently ongoing in the Phase 2 part of the Phase 1/2 clinical trial of RP1 in combination with Opdivo. The Phase
2 part of the clinical trial is currently enrolling 30-patient cohorts with melanoma, non-melanoma skin cancers, metastatic bladder
cancer, and MSI-H tumors. Data from completely enrolled or ongoing skin cancer cohorts is expected to be presented during the second
half of 2020 with further data from all four cohorts expected to be available by year-end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 31pt; text-indent: -9.1pt">&bull;&nbsp;&nbsp;On track to initiate a new registration-directed 125-patient cohort in the Phase 2 clinical trial of RP1 in combination with
Opdivo in anti-PD-1 refractory melanoma patients in the first quarter of 2020, based on the initial clinical efficacy data
with RP1 in melanoma. The additional cohort will be enrolled under an expansion of the clinical trial collaboration and
Opdivo supply agreement with BMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 30pt; text-indent: -9.1pt">&bull;&nbsp;&nbsp;On track to initiate a clinical trial of RP1 as monotherapy in solid organ transplant recipients with CSCC in the first half of
2020. The U.S. Food and Drug Administration (FDA) has accepted the protocol for this clinical trial under its previously-accepted
Investigational New Drug application for RP1. The clinical trial is intended to enroll approximately 30 patients and assess the
safety and efficacy of RP1 in liver and kidney transplant recipients with recurrent CSCC and is expected to provide initial data
by the end of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12pt 0pt 0"><B>RP2: </B>RP2 is a version of RP1 that, in addition
to expressing GALV-GP-R and GM-CSF, also expresses a genetically encoded anti-CTLA-4 antibody intended to block the inhibition
of the initiation of immune response caused by CTLA-4. Similar to RP1, RP2 is intended to be used primarily in combination with
anti-PD-1 therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 30pt; text-indent: -9.1pt">&bull;&nbsp;&nbsp;The Phase 1 clinical trial of RP2 alone and in combination with Opdivo is underway. The clinical trial is designed to assess the
safety and tolerability, and to determine the optimal dose, of RP2 alone and in combination with Opdivo and is being conducted
under a clinical trial collaboration and agreement with BMS for the supply of Opdivo. Initial data from this all-comers trial is
expected by the end of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0"><B>RP3: </B>RP3 is a further armed oncolytic immuno-gene
therapy which expresses two immune co-stimulatory activating ligands &ndash; CD40L and 4-1BBL &ndash; together with anti-CTLA-4
and GALV-GP-R-. CD40L activates CD40, which is intended to result in the broad activation of both innate and adaptive immunity,
and 4-1BBL activates 4-1BB (CD137), which is intended to promote the expansion of cellular and memory immune responses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt">&bull;&nbsp;&nbsp;The Phase 1 clinical trial of RP3 alone and in combination with an anti-PD-1 therapy is expected to initiate in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Updates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 30pt; text-indent: -9.1pt">&bull;&nbsp;&nbsp;<B>Manufacturing: </B>Completed the build-out of Replimune&rsquo;s state of the art manufacturing facility to support late-stage
development and commercialization. The 63,000-square-foot facility in Framingham, MA is intended to provide multi-product manufacturing
capabilities for Replimune&rsquo;s Immulytic product candidates. The Company believes that the capacity of this facility is sufficient
to support full commercialization of its product candidates. An occupancy certificate for the facility has been obtained and the
first technology transfer manufacturing run has been successfully completed. Full GMP manufacturing is expected to commence in
the first half of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 30pt; text-indent: -9.1pt">&bull;&nbsp;&nbsp;<B>Cash Position: </B>Based on its current operating plan, Replimune expects that its cash, cash equivalents and short-term investments,
of approximately $183 million as of December 31, 2019, will be sufficient to fund its operating expenses and capital expenditure
requirements into the second half of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>J.P. Morgan Conference Presentation and Webcast.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">As
previously announced, the Company will be presenting at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January
14<SUP>th</SUP> at 5:00 p.m. PT at the Westin St. Francis Hotel in San Francisco, CA. A simultaneous webcast of the presentation
will be available in the Investors section of Replimune&rsquo;s website at <FONT STYLE="color: #0000EE"><U>www.replimune.com</U></FONT>.
A replay will be available for 30 days following the conference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Replimune</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0"><FONT STYLE="font-size: 10pt">Replimune Group Inc.,
headquartered in Woburn, MA, was founded in 2015 to develop the next generation of &ldquo;oncolytic immune-gene therapies&rdquo;
for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing
effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company&rsquo;s
Immulytic <I><SUP>&trade;</SUP></I> platform is designed to maximize systemic immune activation, in particular to tumor neoantigens,
through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins
to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other
approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical development in combination
with other immuno-oncology products with complementary mechanisms of action. For more information, please visit <FONT STYLE="color: #0000EE"><U>www.replimune.com</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including statements regarding our expectations about our cash runway, our advancement of our clinical
trials, results of our clinical trials, our goals to develop and commercialize our product candidates, our plans to operate
our own in-house manufacturing facility, our expectations with respect to our own in-house manufacturing capabilities, our
proposed investor presentations, and other statements identified by words such as &ldquo;could,&rdquo; &ldquo;expects,&rdquo;
 &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo;
 &ldquo;will,&rdquo; &ldquo;would,&rdquo; or similar expressions and negatives of those terms. Forward-looking statements are
not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are
beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking
statements. These factors include risks related to our limited operating history, our ability to generate positive clinical
trial results for our product candidates, the costs and timing of establishing, equipping, and operating our planned in-house
manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are
subject, competitive pressures, our ability to identify additional product candidates, and other risks as may be detailed
from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the
Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by
such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law,
we undertake no obligation to update or revise these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Replimune Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Inquiries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Brinzey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 419pt 0pt 0">Westwicke, an ICR Company <BR>
339.970.2843<BR>
 <FONT STYLE="color: #0000EE"><U>chris.brinzey@westwicke.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Inquiries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Arleen Goldenberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 405pt 0pt 0">Verge Scientific Communications<BR>
 917.548.1582<BR>
 <FONT STYLE="color: #0000EE"><U>agoldenberg@vergescientific.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Source: Replimune Group Inc</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm203473d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm203473d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !@ 9 # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBCI0
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M7X$L=&U'6O\ A,-%T VVNQ3361M=1M-3N)6V021L) ]G'M8MPI8$ D$?-/\
MP3B_;F^*W[6WC#XK>'_B-I'A73;/P7X7\,ZSI;^'K6ZMI);C6-5U:QN4NC<3
MS;XT2PB,:J5)+N"2,8ZX8'%3PE3'T_9O#TFE*]^97E"#LE>_*YIO39,\RIFV
M$I9A1RV;E'&5[>S]U2BH\DZEVFTK2A3FHM];:'ZU] ?FW$8X4$D]><#)/3C
MY[5,G0^S$'ZC /\ G\>E?C!^W=_P4<^*7[*OQQM_AAX-\$>"?$.DOX*T'Q-)
MJ'B%]86]BNM6NM4AEMY/L$T4$5LJV,13=L<!F.6 R/TB_99^*^K_ !Q_9_\
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MTW700??O^-?"G_!#HAOB;^T(#Q_Q07@,J02&R?$7B8 <=LODGJ,#'&<_<_\
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M-\<-"\2?L^^'?CSJ+PV^B7GP^C\::G(K!887M;(MJ<<>%?8BWT%Q!%E6,2$
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M!_67AWQY'C/ U:.+C3I9[@81GB*$+1>*I2;C]=HQ<FW&G)7JQLO9W7Q)Q/\
M'[Z1WT?<5X*9]A\=E5>KFG!7$&):R;&8B@JF-RK%X>H\3/),RQ5H4*E6.'<J
MF"QE&%.IBL'1=.M'ZQ3DY_T8_P#!&GQ98ZK^SMXE\+(R)>^$?'>H/<1EADP^
M(%;48'(W'@@% "%&??.?U=\4Z)_PD_AW7O#PO9]-77=(O=);4+9%:ZL1?PRV
M[7,,<F$::%)B\9<E ZH65U# _P G?_!.']I^S_9R^.-M:>)]0%C\.?B+!%X9
M\47<H8VFDW<LD?\ 8FM3 '$<=K>".&\G5=RVDK]44@?UK6=Q;WMO!=VEQ#=V
M=U;Q7%M<P2I-;W-M*GF0W$4J!HI8)D/F121N5<,-I(R3_/\ XO9!6P'%6:5:
M]"4LOS]+$T:DU/V=6E6P].AB\.Y0<'&OS>TO34[J$U-RL[+_ $*^B+QWE7%_
M@UP_DE*O1GF_!>$?#N<9<I)5Z&&IXC%RRW%2I<SG.CC,%6C*->$'1=2%2E[3
MVD)0/C#P[^P!^S[I$<;:EI6K>)+WEKB\U35[TQW$C<LXLXI$MH@220L<> >Y
MJ?7_ -@;]G;6H7CM/#^JZ#.4*17.DZQ?0>4Q5AYC6_FM%)@\@.K*2 &!Z5]J
M[@H^5L =AP.OHN3T]/\ Z])N')!))XX )'OSSU[^_;G/\]+PK\._JKP:X(X>
M]CR>R7M<!2E6E!<[YOK,7]9C4DZDI2DZVDK.5W8_I!Y-E"C)?V?1=/FYG-PF
MFG?65^6[=WTBUOZG&_#KP9#\/O!/AWP7!J5YJ]IX<L?[-L[^_2-+N2RBFF:R
MBD$2I&?L=L\-G&RA6>*!'/S%J^"O^"KOBNQ\-?L?>,K&X:$W7BG7?#N@6%L\
M@65FN+PS3S1KN#.8(8Q(X 8)P74@9K](_,2/>&D"*@!)8A%50"<Y[ YP23NX
MR%P5:OY=O^"J_P"U/I7QJ^*6G_"[P5J=MJ/@KX47-Y%>ZI9S">RU?QE,##JT
MT-Q #%=66E1B.P387W7<,SVY8%F'[MX3\-/&\49#A,'AZD,OR)X?$N,93J1P
M^"RNG"GAJ49R4KSG&EAZ<8.IS2FI)RNFW^%?2AXXRS@/P:XIP]7$488[B7+J
MG#&1X*4H.KB*V:0C3KU*=-U%-TL'@E6KU*G)R0BXZRDU%_E%G/UYXR".^<[?
MQP0.>N2.GJ'PD^#/Q(^.?B^S\$?#+PO?>)==NI(O,2&/R;#3+<D))J&JZBQ:
MUTVQ@+8EN'Q'GA00T1DX[PIX7UOQMXH\/^#O#MJ][K_B;6=/T#2+,9)FU/4[
MF*TM8V*Y"1B2XB,\OW8DW.6 !:O[+_V6OV7? G[+GPYT_P &>%+.VN-<G@M)
MO%_BR2&,:EXHUI856[O)Y<,\-F)_,-CIT;K;64!"JA;>S?TMX@<=T^"\%3]A
M2AB<YS!5ZF$HS;]C1Y%"E7J8B4)1K1I)NFJ,:+BZ\X5:<Y1@IJ7^9_T=O #&
M^-6?8I8W%5,HX1R&MA)<08Z@IK&UJ]6-26'RK+I\KH1JSPV&M7Q%2<XX6E.C
M55&I5J4^7X9_9B_X),_#OX7OI/C#XOZ]J/CKQQ +:X;3-%U"_P!"\*:7<!UG
ME@C>QFM;_685PL4BW<@CF97;;Y<@1?UYL;"TT^UM;*RC$5I9P1P6T09F$<,2
MA(X]SLS84 #<S,Q/))R<VM@.>/O,OIP.C$>YX]^G%3"-1TSTQVYXQGIU_KSU
MS7\EYSGV:\0XMX[-\2\56FFHKDITJ="FWS>QI4:48TX4XR;45%MI*\I2DVU_
ML#P'X<\&^&F3PR7@G)*&38-6E5J1E4KXK'UHQ]G.OF&)KU*E7$8BI:\J]J7,
MF_W:M&WQ?_P4+R?V+?VALY_Y$=3GCG&N:/[Y^G'^%?R'_"/6/BSH7C*VO_@K
M=>+++QU':7D=I-X*2[?718R0 7PB%FDDWDM 3Y^ /DXR#M(_KR_X*&H%_8K_
M &A<9_Y$<#KZZYI!/^?P[U_/S_P2+)'[9OAK!Z^#?&PX+9/_ !)LC@'!'3@@
M@<' /(];(ZJH99F57DC4C3L_9STC)<B26TK]$_+7R.;B>A+$9[DE'GE1E65.
M/M8-M0:Q4I-)R=]$[K2U[)6N><7?Q8_X*+:?9W5[J/BO]HZST^TMY)[N[NHO
M$<4%O:0 27$]S,UOM6*-$DN)69XUCC2/.X,0?GKP-X=\??M-_%_PMX/O_&;:
MEXS\>:I!I5MXC\;:W+/&LDY+A'NKFXN)B5!DD@LX&CD,BA8X">*_N.U/3[/5
MM.U#2M2B6YL=5L;O3KVTF.8KBTO(6M;F&1>A26*=D<#D@X'4Y_BI_:5^&FN_
MLN?M/^,?#%BUQ82^$/%T/BOPA> M%++HVH7']KZ'<0%#Y@B#F2S7825A1V/M
MUY/F=#'O$TX87#8;$0H-T73=W?D=K7BFY-]%O?='GY[DM7*H8.M4QV+QV">(
MC"O2JZ*TJC;VG*\=7=Z62\S^IO\ 9_\ V=/#G[&_[..M^$?"=Q_:?B"STC6O
M$_BOQ/)%LG\0^*?[*99;E3M25-/L5M8K33+9B&A@B,S_ .D7$TDG\E'P<^)&
MD?#+XZ>$OB?XGT6Y\4:5X6\<MXDU'1(Y[=;O4XHKN[G:)9[]EA,S.8F9GDY8
M98^;DU_8I\&OB5IO[2O[-GA?QUIT\8/Q!\!3VNL)&X5+'Q*EI<:)XCLSM+&)
M;37+6^BMP5#/;BWG,:K,M?QY_#>+PIX,_: \/V?Q9T9;GPCH'Q'DTWQKH^HJ
M41;"VUF6TU*"^CC82@6ZQO)<H,-&D4KH-RLHY\AE4J+.XXJ,JM:=*]6DU[U9
M0FW-)Z.,FHVC'M976YU\4TZ5)\./"<E#"Q;CA)1E[E*=5TY46[7BX)\SE-NZ
M;:M?;]P?^'XOP^SD_ SQMSD\ZWX<R">HPNHL.I/*LPZXQT'Y-?MP_M0^'/VL
MOBKI/Q'\/^#=0\%1VGA2UT"^L=5N+&YN]1NX+NXF2\,EHYC*>0T<*;F.=BKN
M8#)_IATG]@S]B;7=,T[6M$^#'@?5=(U:SM]1TS4;":\N+&^L+N)9[:[MKF*]
M:*:&>)XY(F1SN5L],U?'_!/C]CH')^!'A,9!S@:D<852  +LG&X9&" "?ESR
M!S8;,<CPE>=?#X#%T:UN7E=627,M'=.5UJG=6NM5NKG?C<EXCS/#_5\5F.75
M*-_:0?L).2;UC[T6DTD]UI):[/3\\-6DU!_^"+&E_P!H"4"/P'HL.GF7&1I:
MZ];&P* ,^Z)8SL3#<8)R!R?D#_@C /\ C+CQ".H'P1\8G&!R!XJ\!*%R!DC"
MKP.<CT&!^O'_  4!\%^&/AU^P%\2?!/@W2+70?"WAS0-%T_1='L@T=K8V4.L
M6K)##YK?*@R>#(V2<#+5^1/_  1@4G]K3Q*5!8+\$?%NX@-M42>*_ NQ>%P"
MP4.!N!/S#)VD5T4*D:V39O5@I*,\1B9J-K2Y*TDXN23TT3YM7:[>MM>'%T)8
M7B+ANC.2D\/A,-AI/>,YN%6"J-O>//!\DFM7RJROI_4N$((()QD9!  '/(/0
M 8/U([[NG\47[7_AS3O /[7_ ,:O#VC0K;:=H7Q36>U2#Y1']MAT?7Y/*!)*
MEIKQI6))/G,5&5'']HWB'Q%H_A31-5\2>)=2L]$\/Z)8S:CJVJZC.MM9V-E;
M1^9-<3SN-@"@%5CW%Y9&2*-6E=%;^)+XR>,3\=/VF?&OC+1XI;Q?B'\44ETA
M43=-?6LE_9Z5I\J1GYBMU96:W,:']X(SMQC&.;A6,E6Q<G%PHQH3OJW&4U";
M5V[+J^MU>]E<[..)1EA\!17++$_6*<H<MN=14Z:;LM=TM+-735]-/WP_X*7Z
MHVN?\$\_AIK3O)(^K:C\*M1>28YF=KWPCJ,Q:4X'[PF3Y\ <@CWKY9_X(<?\
ME-_:$SU_X0#P'GZCQ%XE!_4=J^O/^"I^CMX>_8/\'Z VP/H?B3X<:41&FQ0^
MG^&=3MB%3)VC,6 O;]*^0?\ @AR<?$[]H3G_ )D+P$,>F?$?B;K^ /Y^F*NB
MU+AK,FY17^U3Y5?5_OX-Z6M9K7?H98F+_P!<<J3WCE]-R<M/^8:>E^K;LK6W
MN>*?\%E_^3N;7_LE'@__ -.'B*OVA_9!S_P[D^''O\!-:^G.D:N.OXFOQ>_X
M+*<_M>6H)&#\)O"!'_@?XA_EUSQUZXX/[1?L@$?\.Y/AO@C(^ FMDXR1C^QM
M6/J#Z\_4],9,;_R(\@_Z^4_PJ/3;1]N]F&7)KB3B9J[YJ&)5XV?(TZ/Q)M<K
M?*[?\$_G$_81^7]LSX#$$C/Q.TKIP<?;=H4]#MQ(Q9>A.UF!*J1_: J D'.,
M,,C ((!X !'?G.1D \$5_%_^PES^V9\!>G_)3M+/UQ?(<]/3Z_6O[0\ E3_=
M_NX +#)YXZ$#MZUS<4?[UAK.5HX6FUJT[\R_!IM?.]CMX);CE^,7/S)YC77-
M9.]X-6OZZ_*Q_''_ ,%-M'M-'_;&^,<5HFU=1_L[5KC;@'[7J=C)-<LQ '+.
M<L?O-M!8]Z_JQ_9U>2Y^ _PBN+B1I)#\._"P+LVYFVZ3:A>>?N*H5 , *%&/
MER/Y8_\ @J:?^,S/BL#T&F^'@,#(/_$LDZ^^%Y)Z'ZBOZFOV<"!^S_\ " '&
M?^%>^&!Z]-)MQG]/K^1%;9RXRRC*FDE-3=VI/;V=+XM%;\4]5V9S<-*4<^SZ
M$5)14HQERV7.U4JN[7DI:/35O0_&G_@N?:6ZI^S+>B-1=3R_%RTEG48=[>UB
M^'4T$;'^)8GNKO:",8N)<@E@1[W_ ,$9YYI/V7_&4$DC/#;_ !#UGR8V(VQ&
M73[-GV@<#>P'/4[0>N:\,_X+I_\ 'E^S#SD&^^,1YYQFT^&6#^'Y_7->Y?\
M!&",R_LT^,HP<!_B/J"M@<@-IMH,^G&=V!^O8J+FX7HWBTUC7:3UCI4E=7[I
M-6T[FE*/+QIB)1C*W]GZI2YFY2IPNW'W;;VZW>NEF?A%IW_)Y]Q_V<[XA_\
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M#SPH ) _+U/7W-1Q.O\ :<'[KCS4(RO=KF4ES*UM;--7VUNM+E\$<RPV9/\
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M>%6\2^,=)M+SPSXCTZTFL;.YFTE95O=)U'[1>W-O'-):W$D]M@R;EMRHR4)
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MD?LL?\% ?!L4VE>'OA5\:] MXICYEIHM_!;6@E48S&MEK(MSA0 IB)0  )@
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
